Effect of Alteplase Administration on International Normalized Ratio in Patients With Acute Ischemic Stroke

Abstract

Background/Objective:

Alteplase may elevate international normalized ratio (INR) results, although the exact rate of elevation occurrence is not firmly established in the literature. The purpose of this study is to determine the occurrence rate of INR elevation following alteplase administration. We also aimed to determine what factors are independently associated with the development of elevated INR following alteplase administration for ischemic stroke.

Methods:

We conducted a multicenter, retrospective, cohort study of patients who received alteplase for acute ischemic stroke. Patients were screened for baseline INR measurement and a repeat value within 24 hours of alteplase administration. The primary outcome was the percent of patients who experienced ≥0.4-point increase in INR. Secondary outcomes included the rate of adverse bleeding events and identification of factors independently associated with elevated INR following alteplase administration.

Results and Conclusions:

Two hundred and sixty-one patients were included, with 44 (16.9%) patients having an INR increase of 0.4 or more. Patients with an INR increase ≥0.4 experienced a nonstatistically significant increase in bleeding episodes (8.8% vs 18.2%; P = .10). We identified African American race (odds ratio, 3.48, 95% confidence interval, 1.5-7.6; P = .002) as an independent predictor of INR increase ≥0.04. An INR elevation is common following receipt of alteplase for ischemic stroke. Those of African American race were at increased risk of INR elevation; however, more studies are needed to determine whether these patients are at a higher bleeding risk as a result of INR elevation.

Keywords

ischemic stroke alteplase INR hemorrhagic transformation

Get full access to this article

View all access options for this article.

References

Benjamin

Virani

Callaway

, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. doi:10.1161/CIR.0000000000000558.

Powers

Rabinstein

Ackerson

, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110. doi:10.1161/STR.0000000000000158.

Jauch

Saver

Adams

, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947. doi:10.1161/STR.0b013e318284056a.

Lee

Conners

Cutting

Song

Bernstein

Prabhakaran

. Elevated international normalized ratio as a manifestation of post-thrombolytic coagulopathy in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014;23(8):2139–2144. doi:10.1016/j.jstrokecerebrovasdis.2014.03.021.

Chapin

Hajjar

. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29(1):17–24. doi:10.1016/j.blre.2014.09.003.

National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587. doi:10.1056/NEJM199512143332401.

Vandelli

Marietta

Gambini

, et al. Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2015;24(2):394–400. doi:10.1016/j.jstrokecerebrovasdis.2014.09.005.

Hacke

Kaste

Bluhmki

, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329. doi:10.1056/NEJMoa0804656.

Hacke

Kaste

Fieschi

, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet (Lond, Engl). 1998;352(9136):1245–1251. doi:10.1016/s0140-6736(98)08020-9.

10.

Howard

McClure

Moy

, et al. Self-reported stroke risk stratification: reasons for geographic and racial differences in stroke study. Stroke. 2017;48(7):1737–1743. doi:10.1161/STROKEAHA.117.016757.

11.

Mensah

Mokdad

Ford

Greenlund

Croft

. State of disparities in cardiovascular health in the United States. Circulation. 2005;111(10):1233–1241. doi:10.1161/01.CIR.0000158136.76824.04.

12.

Lutsey

Cushman

Steffen

, et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost. 2006;4(12):2629–2635. doi:10.1111/j.1538-7836.2006.02237.x.

13.

Switzer

Rocker

Mohorn

, et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. Stroke. 2012;43:2500–2502. doi:10.1161/STROKEAHA.112.661454.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB